Pfizer announced that it is exploring options for early-stage treatments for rare diseases and cancer.
The company’s studies are an attempt to focus on “high-impact” drugs and vaccines, Pfizer said Thursday.
The American drugmaker said those evaluated options include collaborations with other drug developers or the formation of a new company.
Pfizer plans to focus on developing treatments for rare diseases internally using technologies such as gene editing, while exploring external opportunities for early-stage gene therapy programs and its Colorado cancer research facility.
The company is also expected to look to externally promote its North Carolina gene therapy facility. This would allow the company, which has been investing heavily in its internal drug pipeline and closing deals to increase revenue, to focus its portfolio of experimental treatments on areas where the company believes it is “better positioned”.
“We believe these actions will position us to lead the industry in reaching more patients,” said a Pfizer spokesperson.
In August 2022, Pfizer announced a $4.5 billion deal for global sickle cell pharmaceutical company Global Blood Therapeutics, months after its $11.6 billion deal for Biohaven Pharmaceutical Holding.
Source: CNN Brasil
A journalist with over 7 years of experience in the news industry, currently working at World Stock Market as an author for the Entertainment section and also contributing to the Economics or finance section on a part-time basis. Has a passion for Entertainment and fashion topics, and has put in a lot of research and effort to provide accurate information to readers.
